SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-262071
Filing Date
2024-11-20
Accepted
2024-11-20 06:07:00
Documents
15
Period of Report
2024-11-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d871395d8k.htm   iXBRL 8-K 25842
2 EX-99.1 d871395dex991.htm EX-99.1 6182
6 GRAPHIC g871395g1120061253435.jpg GRAPHIC 3279
  Complete submission text file 0001193125-24-262071.txt   162089

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA lnth-20241120.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lnth-20241120_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lnth-20241120_pre.xml EX-101.PRE 11265
17 EXTRACTED XBRL INSTANCE DOCUMENT d871395d8k_htm.xml XML 3641
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

IRS No.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36569 | Film No.: 241478135
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)